September 2023 Snap Recap: Prostate Cancer Awareness, Breast Cancer QOL Insights

As we enter the final leg of 2023, CancerNetwork^® looks back on the biggest news pieces of September as decided on by our readers. Popular selections included articles on the clearance of an investigational new drug application for a CDK12/13 inhibitor, the quality-of-life benefits of a certain diet and exercise intervention in breast cancer, how AI may help with diagnosis and risk stratification in prostate cancer, the impact of adaptive stereotactic body radiotherapy on toxicities in prostate cancer, and recurrence risk following breast-conserving surgery and endocrine therapy for luminal breast cancer.^1-4

Full versions of the article are referenced below in the order that they appear in the show:

• FDA Clears IND Application for First-in-Class CDK12/13 Inhibitor by Hayley Virgil¹
• AI May Assist in Prostate Cancer Diagnosis, Risk Stratification, and Treatment by Wayne G. Brisbane
• Adaptive SBRT May Reduce GU/GI Toxicity Risk in Prostate Cancer by Russ Conroy²
• Diet and Exercise Intervention Associated With Better pCR in TNBC or HR+, HER2– BC by Hayley Virgil³
• Recurrence Low After BCS and Endocrine Therapy for Luminal Breast Cancer by Hayley Virgil⁴

References

1. Carrick Therapeutics announces U.S. FDA clearance of IND for CT7439, a first-in-class inhibitor of CDK12/13. News release. Carrick Therapeutics. September 7, 2023. Accessed September 7, 2023. https://bit.ly/3Z9GoN9
2. Leeman JE, Shin KY, Chen YH, et al. Acute toxicity comparison of magnetic resonance-guided adaptive versus fiducial or computed tomography-guided non-adaptive prostate stereotactic body radiotherapy: a systematic review and meta-analysis. Cancer. Published online July 24, 2023. doi:10.1002/cncr.34836
3. Sanft T, Harrigan M, McGowan C, et al. Randomized trial of exercise and nutrition on chemotherapy completion and pathologic complete response in women with breast cancer: the lifestyle, exercise, and nutrition early after diagnosis study. J Clin Oncol. Published online September 1, 2023. doi:10.1200/JCO.23.00871
4. Whelan TJ, Smith S, Parpia S, et al. Omitting radiotherapy after breast-conserving surgery in luminal A breast cancer. N Engl J Med. 2023;389:612-619. doi:10.1056/NEJMoa2302344